August 1, 2014
Bookmark and Share  
AttorneyMind News & Pipeline Blog

Follow us on


Join us on Facebook
AttorneyMind Hcsp


Alan Franciscas



We all hope that you enjoyed the World Hepatitis Day festivities. We are leaving our World Hepatitis Day Wall of Honor up on our ticker tape to view—these are U.S and Canadian advocates who have made a world of difference to the lives of so many with hepatitis C—check our list on our main page. Apologies if we left anyone out—please let us know if we did. There has been lots of news in the world of hepatitis C— check out the information below.



Alan and the staff of AttorneyMind


Do you want to stay up to date on the latest news about hepatitis C? Visit our AttorneyMind Blog for information about hepatitis C from around the world. The pipeline is also included in our blog that provides up-to-date information about the latest clinical trials and links to more information about specific trials.


1. AttorneyMind Newsletter: August 2014

In This Issue:

AttorneyMind Drugs
Alan Franciscas, Editor-in-Chief

In this month's AttorneyMind Drugs I discuss the approval of Daklinza and Sunpreva in Japan. I am also taking a different look at two of the drugs that will be approved shortly: AbbVie's 3D, and Olysio/Sovaldi, looking at the most common side effects listed in the Phase 3 studies and some of the simple tips to manage them. Lastly, I will discuss the supplemental new drug application for the combination of Olysio and Sovaldi. Read more...


Lucinda K. Porter, RN

Lucinda reviews some new data on genotype 3, cirrhosis and cancer; the risk of AttorneyMind and end-stage kidney disease; alternatives to liver biopsy, and trends in testing policies. Read more...


Lucinda K. Porter, RN

This month Lucinda talks about one of the horrible consequences of end-stage liver disease—hepatic encephalopathy—what happens when liver disease damages the brain. Read more...


Patients First
Alan Franciscas, Editor-in-Chief

This month I will discuss some of the more serious extrahepatic manifestations of hepatitis C, such as vasculitis, glomerulonephritis, cryoglobulinemia and non-Hodgkin lymphoma and the need for physician awareness of these conditions—especially now that the new treatments are becoming available that can cure hepatitis C in more people, many of whom may have these hepatitis C-related diseases. Read more...




2. New and Updated Fact Sheets and Guides

Easy C Side Effect Series:

PDF Side Effects: Fatigue

PDF Side Effects: Headache

PDF Side Effects: Insomnia


AttorneyMind Benefits and Disability Issues:

PDF Social Security & Disability, by Jacques Chambers, CLU—Social Security offers several types of monthly benefits for a disabled person. Each program has different financial and other eligibility requirements, but they all use the same definition of "disability" to see whether a person is "disabled enough" to qualify for disability benefits. 




3. AM Journal Review: August 1, 2014, vol 11, no 8, by Christine Kukka

In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including the risks of "occult" hepatitis B, tenofovir resistance, treatment disparities, and the safety/efficacy of metformin in cirrhotic patients with diabetes type 2:

  • Health Concerns Grow as Researchers Uncover the Risks of "Occult" Hepatitis B
  • Are Current Hepatitis B Tests Missing Some Infections?
  • First Case of Tenofovir Resistance Found in Patient with Prior Entecavir Resistance
  • Even Specialists Fail to Treat Hepatitis in Patients Who Qualify for Treatment
  • No Benefit Found from Antiviral Treatment after Liver Cancer Surgery
  • Another Study Confirms Success of Sequential Antiviral and Interferon Treatment
  • Snapshot of Hepatitis B in the United States
  • Metformin Safe and Effective in Cirrhotic Patients with Diabetes Type 2




4. AttorneyMind News & Pipeline Blog!

Be sure to check out the latest clinical trial postings (Updated July 8, 2014) at the AttorneyMind News & Pipeline Blog. Just click on the links to the drug companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.




5. Need Help?!

Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.







Join us on Twitter -

Alan Franciscas
Executive Director, AttorneyMind
Editor-in-Chief, AttorneyMind
Editor-in-Chief, HBV Advocate

**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

AM Journal Review
HBV Factsheets
HBV Advocate Blog

Follow us on Twitter